ValuEngine cut shares of Nuvectra (NASDAQ:NVTR) from a hold rating to a sell rating in a research note released on Friday.

Separately, Piper Jaffray Companies reaffirmed a hold rating and set a $12.00 price objective on shares of Nuvectra in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $12.00.

Shares of Nuvectra (NASDAQ NVTR) traded up $0.16 on Friday, reaching $9.06. 23,613 shares of the company traded hands, compared to its average volume of 66,190. Nuvectra has a 12 month low of $4.90 and a 12 month high of $15.00. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37.

Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.07. The company had revenue of $7.60 million for the quarter, compared to analysts’ expectations of $8.08 million. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. Nuvectra’s quarterly revenue was up 100.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.92) earnings per share. analysts anticipate that Nuvectra will post -4.77 EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of NVTR. OxFORD Asset Management LLP purchased a new position in Nuvectra during the second quarter worth $154,000. Wolverine Trading LLC purchased a new position in Nuvectra during the second quarter worth $156,000. Group One Trading L.P. purchased a new position in Nuvectra during the second quarter worth $167,000. FNY Partners Fund LP boosted its stake in Nuvectra by 449.6% during the third quarter. FNY Partners Fund LP now owns 13,740 shares of the company’s stock worth $182,000 after buying an additional 11,240 shares during the period. Finally, Stifel Financial Corp boosted its stake in Nuvectra by 6.2% during the second quarter. Stifel Financial Corp now owns 34,227 shares of the company’s stock worth $444,000 after buying an additional 1,999 shares during the period. 58.89% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dailypolitical.com/2017/12/02/nuvectra-nvtr-downgraded-to-sell-at-valuengine.html.

About Nuvectra

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.